journal article·2019-12-04Open access

Cancer cell membrane cloaking nanoparticles for targeted co-delivery of doxorubicin and PD-L1 siRNA

Mushi Chen, Ming Chen, Jiantai He

Abstract

Nanoparticles coated with cell membranes have been garnering growing attention due to their homologous binding capability of membrane molecules and consequent self-recognition by their source cells. In the present study, we report on the construction of doxorubicin and PD-L1 siRNA-loaded PLGA nanoparticles and their biological functionalization by cancer cell-derived membrane cloaking. The resulting cancer cell membrane-coated nanoparticles (CCMNPs) presented a core-shell nanostructure with highly specific self-recognition affinity to the homotypic cells, which can be attributed to the transference of cell adhesion molecules with homotypic binding properties. These findings facilitate the application of this bioinspired strategy for effective delivery of siRNA and precise tumour therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Xiangya Hospital, Central South University

Nanhai District People’s Hospital

References (35)

Show source-provided references
1. 10.1002/smll.20180410510.1002/smll.201804105 ↗
2. 10.1016/j.addr.2012.10.00210.1016/j.addr.2012.10.002 ↗
3. 10.1016/j.addr.2015.01.00210.1016/j.addr.2015.01.002 ↗
4. 10.1021/acs.nanolett.6b0278610.1021/acs.nanolett.6b02786 ↗
5. 10.1016/j.apsb.2017.11.00910.1016/j.apsb.2017.11.009 ↗
6. 10.1038/nrd349910.1038/nrd3499 ↗
7. 10.1002/adma.20120022410.1002/adma.201200224 ↗
8. 10.1039/c3nr00015j10.1039/c3nr00015j ↗
9. 10.1039/C3NR06371B10.1039/C3NR06371B ↗
10. 10.1056/NEJMoa101286310.1056/NEJMoa1012863 ↗
11. 10.1016/j.vaccine.2008.07.03510.1016/j.vaccine.2008.07.035 ↗
12. 10.1073/pnas.110663410810.1073/pnas.1106634108 ↗
13. 10.1021/nl500618u10.1021/nl500618u ↗
14. 10.1038/sj.cdd.440223710.1038/sj.cdd.4402237 ↗
15. 10.1002/adhm.20150008910.1002/adhm.201500089 ↗
16. 10.1080/21691401.2018.147052410.1080/21691401.2018.1470524 ↗
17. 10.1016/j.nano.2017.08.00710.1016/j.nano.2017.08.007 ↗
18. 10.1002/iub.47810.1002/iub.478 ↗
19. 10.2217/nnm.12.15310.2217/nnm.12.153 ↗
20. 10.1038/nature1537310.1038/nature15373 ↗
21. 10.1002/adma.20150608610.1002/adma.201506086 ↗
22. 10.1016/j.addr.2015.04.00110.1016/j.addr.2015.04.001 ↗
23. 10.1038/nnano.2013.5410.1038/nnano.2013.54 ↗
24. 10.1002/adma.20170675910.1002/adma.201706759 ↗
25. 10.1016/j.biomaterials.2017.02.04110.1016/j.biomaterials.2017.02.041 ↗
26. 10.1021/acsnano.6b0469510.1021/acsnano.6b04695 ↗
27. 10.1002/adma.20130063810.1002/adma.201300638 ↗
28. 10.1002/adhm.20120013810.1002/adhm.201200138 ↗
29. 10.1038/nbt.215710.1038/nbt.2157 ↗
30. 10.1158/0008-5472.CAN-11-372210.1158/0008-5472.CAN-11-3722 ↗
31. 10.1038/nrd261410.1038/nrd2614 ↗
32. 10.1083/jcb.20091010410.1083/jcb.200910104 ↗
33. Iurisci I, Cumashi A, Sherman AA, et al. Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. Anticancer Res. 2009;29:403–410.
34. 10.1074/jbc.M20959020010.1074/jbc.M209590200 ↗
35. Glinsky VV, Glinsky GV, Glinskii OV, et al. Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res. 2003;63:3805–3811.